Relation between cytokine promoter gene polymorphism and toxicity of 5-fluorouracil plus cisplatin chemotherapy

Oncology Reports

Volumn 16, Issue 2, 2006, Pages 381-387

  Sakamoto, Kazuhiko ^a   Oka, Masaaki ^a   Yoshino, Shigehumi ^a   Hazama, Shoichi ^a   Abe, Toshihiro ^a   Okayama, Naoko ^a   Hinoda, Yuji ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

IL 1 511 C T polymorphism; IL 6 634 C G polymorphism; TNF 1031 T C polymorphism

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CISPLATIN; CYTOKINE; FLUOROURACIL;

ADULT; AGED; ARTICLE; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; NEOPLASM; PROMOTER REGION;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CISPLATIN; CYTOKINES; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS);

EID: 33748530651     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.2.381     Document Type: Article

References (49)

1. Boddy AV and Idle JR: The role of pharmacogenetics in chemotherapy: modulation of tumour response and host toxicity. Cancer Surv 17: 79-104, 1993.
2. Van Kuilenburg AB, Meinsma R, Zoetekouw L and van Gennip AH: Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Int J Cancer 101: 253-258, 2002. (Pubitemid 34970893)
3. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A and Gamelin E: Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 10: 5151-5159, 2004. (Pubitemid 39099790)
4. Lecomte T, Ferraz JM, Zinzindohoue F, et al: Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 10: 5880-5888, 2004. (Pubitemid 39180969)
5. Okuda K, Tanaka M, Shibata J, et al: Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncol Rep 6: 587-591, 1999.
6. Sekiguchi H, Akiyama S, Fujiwara M, et al: Phase II trial of 5-fluorouracil and low-dose cisplatin in patients with squamous cell carcinoma of the esophagus. Surg Today 29: 97-101, 1999. (Pubitemid 29088853)
7. Tsuji A, Morita S, Horimi T, Takasaki M, Takahashi I and Shirasaka T: Combination chemotherapy of continuous 5-FU infusion and low-dose cisplatin infusion for the treatment of advanced and recurrent gastric and colorectal adenocarcinomas. Gan To Kagaku Ryoho 27: 528-534, 2000.
8. Shirasaka T, Shimamoto Y, Ohshimo H, Saito H and Fukushima M: Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 32: 167-172, 1993. (Pubitemid 23146807)
9. Hirata K, Yamamitsu S, Tsuji A, et al: Biochemical modulation of 5-FU-effect of low dose CDDP. Gan To Kagaku Ryoho 26: 467-475, 1999.
10. Furuhata T, Hirata K, Yamamitsu S, et al: Combination chemotherapy of continuous infusion 5-FU and daily low-dose CDDP in colorectal carcinoma. Gan To Kagaku Ryoho 26: 1554-1558, 1999.
11. Wei X, McLeod HL, McMurrough J, Gonzalez FJ and Fernandez-Salguero P: Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 98: 610-615, 1996. (Pubitemid 26349163)
12. Van Kuilenburg AB, Vreken P, Beex LV, et al: Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Eur J Cancer 33: 2258-2264, 1997. (Pubitemid 28123420)
13. Kouwaki M, Hamajima N, Sumi S, et al: Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity. Clin Cancer Res 4: 2999-3004, 1998. (Pubitemid 29001473)
14. Yamaguchi K, Arai Y, Kanda Y and Akagi K: Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-Fluorouracil. Jpn J Cancer Res 92: 337-342, 2001. (Pubitemid 32288297)
15. Le J and Vilcek J: Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab Invest 56: 234-248, 1987. (Pubitemid 17065343)
16. Carter DB, Deibel MR Jr, Dunn CJ, et al: Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 344: 633-638, 1990.
17. Taub DD and Oppenheim JJ: Chemokines, inflammation and the immune system. Ther Immunol 1: 229-246, 1994. (Pubitemid 24278716)
18. Okamura H, Tsutsui H, Komatsu T, et al: Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378: 88-91, 1995.
19. Swope MD and Lolis E: Macrophage migration inhibitory factor: cytokine, hormone or enzyme? Rev Physiol Biochem Pharmacol 139: 1-32, 1999.
20. Higuchi T, Seki N, Kamizono S, et al: Polymorphism of the 5′-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens 51: 605-612, 1998. (Pubitemid 28306464)
21. Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE and Greenspan SL: Two promoter polymorphisms regulating inter-leukin- 6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab 88: 255-259, 2003. (Pubitemid 36115175)
22. Brull DJ, Montgomery HE, Sanders J, et al: Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 21: 1458-1463, 2001. (Pubitemid 34219808)
23. Takamatsu Y, Akashi K, Harada M, et al: Cytokine production by peripheral blood monocytes and T cells during haemopoietic recovery after intensive chemotherapy. Br J Haematol 83: 21-27, 1993. (Pubitemid 23030166)
24. Chen YM, Whang-Peng J, Liu JM, Wang SY, Tsai CM and Perng RP: Elevation of serum interleukin-6 levels before peak of serum granulocyte colony-stimulating factor level in chemo-therapy- induced myelosuppressive patients. J Immunother Emphasis Tumor Immunol 17: 249-254, 1995.
25. Chen YM, Whang-Peng J, Liu JM, et al: Serum cytokine level fluctuations in chemotherapy-induced myelosuppression. Jpn J Clin Oncol 26: 18-23, 1996. (Pubitemid 126469261)
26. Bravo L, Legendre AM, Hahn KA, Rohrbach BW, Abraha T and Lothrop CD Jr: Serum granulocyte colony-stimulating factor (G-CSF) and interleukin-1 (IL-1) concentrations after chemo-therapy- induced neutropenia in normal and tumor-bearing dogs. Exp Hematol 24: 11-17, 1996. (Pubitemid 26041771)
27. Wang L, Hirayasu K, Ishizawa M and Kobayashi Y: Purification of genomic DNA from human whole blood by isopropanolfractionation with concentrated Nal and SDS. Nucleic Acids Res 22: 1774-1775, 1994. (Pubitemid 24155844)
28. Tarlow JK, Blakemore AI, Lennard A, et al: Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 91: 403-404, 1993. (Pubitemid 23177503)
29. Hamajima N, Saito T, Matsuo K, Kozaki K, Takahashi T and Tajima K: Polymerase chain reaction with confronting two-pair primers for polymorphism genotyping. Jpn J Cancer Res 91: 865-868, 2000.
30. Ye S, Dhillon S, Ke X, Collins AR and Day IN: An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res 29: 88, 2001.
31. Okayama N, Fujimura K, Nakamura J, Suehiro Y, Hamanaka Y and Hinoda Y: Evaluation of a new efficient procedure for single-nucleotide polymorphism genotyping: tetra-primer amplification refractory mutation system-polymerase chain reaction. Clin Chem Lab Med 42: 13-16, 2004. (Pubitemid 38401462)
32. Kolb HJ: Bone marrow morbidity of radiotherapy. In: Complications of Cancer Management. Plowman PN, McElwain T and Meadows A (eds). Butterworth-Heineman, Oxford, pp398-411, 1991.
33. Biffl WL, Moore EE, Moore FA, Barnett CC Jr, Carl VS and Peterson VN: Interleukin-6 delays neutrophil apoptosis. Arch Surg 131: 24-30, 1996. (Pubitemid 26015403)
34. Terry CF, Loukaci V and Green FR: Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 275: 18138-18144, 2000. (Pubitemid 30414764)
35. Hsu HC, Tsai WH, Jiang ML, et al: Circulating levels of thrombopoietic and inflammatory cytokines in patients with clonal and reactive thrombocytosis. J Lab Clin Med 134: 392-397, 1999.
36. Kimura H, Ishibashi T, Shikama Y, et al: Interleukin-1 beta (IL-1 beta) induces thrombocytosis in mice: possible implication of IL-6. Blood 76: 2493-2500, 1990.
37. Araneda M, Krishnan V, Hall K, Kalbfleisch J, Krishnaswamy G and Krishnan K: Reactive and clonal thrombocytosis: proinflammatory and hematopoietic cytokines and acute phase proteins. South Med J 94: 417-420, 2001. (Pubitemid 33643432)
38. Fernandez-Real JM, Vendrell J, Richart C, Gutierrez C and Ricart W: Platelet count and interleukin 6 gene polymorphism in healthy subjects. BMC Med Genet 2: 6, 2001.
39. Fishman D, Faulds G, Jeffery R, et al: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 level, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102: 1369-1376, 1998. (Pubitemid 28467565)
40. Santtila S, Savinainen K and Hurme M: Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scand J Immunol 47: 195-198, 1998. (Pubitemid 28153395)
41. Pico JL, Avila-Garavito A and Naccache P: Mucositis: its occurrence, consequences and treatment in the oncology setting. Oncologist 3: 446-451, 1998. (Pubitemid 29009309)
42. Lockhart PB and Sonis ST: Alterations in the oral mucosa caused by chemotherapeutic agents. A histologic study. J Dermatol Surg Oncol 7: 1019-1025, 1981. (Pubitemid 12197971)
43. Guggenheimer J, Verbin RS, Apple BN, et al: Clincopathologic effects of cancer chemotherapeutic agents on human buccal mucosa. Oral Surg Oral Med Oral Pathol 44: 58-63, 1997.
44. Krenger W and Ferrara JL: Graft-vs-host disease and the Th1/Th2 paradigm. Immunol Res 15: 50-73, 1996.
45. Aggarwal BB, Kohr WS and Hass PE: Human tumor necrosis factor. Production, purification and characterization. J Biol Chem 260: 2345-2354, 1985. (Pubitemid 15104839)
46. Buno IJ, Huff JC, Weston WL, Cook DT and Brice SL: Elevated levels of interferon gamma, tumor necrosis factor alpha, interleukins 2, 4 and 5, but not interleukin 10, are present in recurrent aphthous stomatitis. Arch Dermatol 134: 827-831, 1998. (Pubitemid 28350186)
47. Taylor LJ, Bagg J, Walker DM and Peters TJ: Increased production of tumour necrosis factor by peripheral blood leukocytes in patients with recurrent oral aphthous ulceration. J Oral Pathol Med 21: 21-25, 1992.
48. Wilson AG, Symons JA, McDowell TL, McDevitt HO and Duff GW: Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 94: 3195-3199, 1997. (Pubitemid 27157287)
49. Bazrafshani MR, Hajeer AH, Ollier WE and Thornhill MH: Recurrent aphthous stomatitis and gene polymorphisms for the inflammatory markers TNF-alpha, TNF-beta and the vitamin D receptor: no association detected. Oral Dis 8: 303-307, 2002. (Pubitemid 35434333)